Top 25 Biosimilar Drug Manufacturers 2019 - Visiongain Research Report
Celltrion and Teva announce first Rituxan biosimilar approval in US
Teva: Biosimilars In The US Will Become Like Complex Generics :: Generics Bulletin
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership | World Pharma Today
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Celltrion's Truxima (rituximab-abbs) Biosimilar Product Profile
Biosimilars encircle Rituxan, US debates innovator exclusivity | Nature Biotechnology
Global Rituximab Biosimilar Market Assessment –Clinical Trial/Pipeline Analysis, Brand/Originator Drug Historic Revenue and Forecast 2019- 2027 | Medgadget
Teva and Celltrion Launch Truxima (biosimilar- rituximab) to Treat Wegener's Granulomatosis and Microscopic Polyangiitis in the US
Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA
The U.S. Biosimilars Market: Shaking The “Laggard” Label | Contract Pharma
Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech
Biosimilars 2020 Year in Review | Fish & Richardson - JDSupra
Teva and Celltrion Launch Rituximab Biosimilar in US - Big Molecule Watch
Roche faces prospect of second Rituxan biosimilar in US - PMLiVE
Riabni™ (rituximab-arrx) – New biosimilar approval
FDA panel unanimously backs Celltrion's Rituxan biosimilar | Fierce Pharma
Teva launches biosimilar to Roche's Rituxan
The First Rituxan Biosimilar Is Expected to Be Approved by FDA – Creative Biolabs rAb Blog
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership - Drug Discovery and Development
Teva Pharmaceuticals 63459010450 - McKesson Medical-Surgical
Top developments in biosimilars during 2019 - GaBI Journal
Teva launches rituximab biosimilar Truxima in US
Teva teams with Celltrion in $160m biosimilar deal - Globes
Teva settles with Roche to launch first Rituxan biosimilar in US - BioProcess InternationalBioProcess International
Roche's patent cliff just got steeper as FDA approves Celltrion's Rituxan biosimilar Truxima | Fierce Pharma
